CARM Company Profile and Key Details

CARM has shown weak momentum, losing -68.16% over the past week and -87.43% over the past quarter, though year-to-date performance is down -88.3%. Short-term trend indicators are bullishly aligned (SMA20 -44.21%, SMA50 -47.17%, SMA200 -55.31%). The stock’s 14-day RSI is 29.98 (weak momentum), while the ATR of 0.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.88% below its high and over 8.61% above its low. Average 10-day trading volume of 43.39 thousand shares is below the 3-month average of 64.20 thousand, indicating normal recent market interest.

Carisma Therapeutics, Inc. generated EPS of -$1.18 over the past year. Five-year average earnings growth is 42.71%. Wall Street analysts project EPS growth of 32.95% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.12. Next year's EPS is expected at $15.49. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $1.00 to $1.00. The high target offers 3233.33% upside. The low target suggests 3233.33% downside. The mean target is $1.00. This offers 3233.33% upside. Carisma Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 07, 2025, missed forecasts by 0.0%. The prior quarter beat by 83.33%. Over the last six quarters, Apple has recorded several small beats. These include 24.32% in May 09, 2024.

Carisma Therapeutics, Inc. has 41.79 million shares outstanding. The public float is 34.65 million shares, elevated short interest at 1.55% of float. This equals 560.93 thousand shares. The short ratio is 1.34 days. Institutional investors hold 27.42% of the float. Insiders own 27.76%. Hodits Regina holds 2.30 million shares, Cannell Thomas R has 672.39 thousand shares and Kelly Steven has 600.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 541.33 thousand shares across 4 transactions.

Carisma Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.37. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.03 and $1.27. With a market capitalization of about $1.39 million, Carisma Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.58). Key stats such as the average daily volume over the past year has been around 129.22 thousand shares, volume is running light vs its 52-week average. Headquartered in Philadelphia, PA, Carisma Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Saar Gill, the company employs approximately 46 people and listed since February 06, 2014. Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors.

Carisma Therapeutics, Inc. trades at a P/E ratio of 0.19, slightly below the S&P 500 average, with a price-to-sales ratio of 0.03 and a price-to-book ratio of -1.81 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.07, also below market averages.

Carisma Therapeutics, Inc. (NASDAQ:CARM) shares are down -88.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Carisma Therapeutics, Inc. trading at a premium to the broader market with a P/E of 0.19. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.40, suggesting 28298.79% upside. Our AI forecast model points to short-term weakness (-9.37% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-69.79% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Carisma Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.37%, with price expected at $0.03 by April 08, 2026, within a range of $0.02 to $0.04 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by June 22, 2026, with a range of $0.00 to $0.03. 1-Year Outlook: Projected loss of -69.79%, with price at $0.01 by March 25, 2027, within a range of $0.00 to $0.15.